Evidence map›Paper›PMID 15767426›Full record

ArticleJournal of virology2005

Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2.

Grant A Darnell, Toni M Antalis, Barbara R Rose, Andreas Suhrbier

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 14 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Grant A DarnellQueensland Institute of Medical Research, University of Queensland, Brisbane, Queensland, Australia.
Toni M Antalis
Barbara R Rose
Andreas Suhrbier
QIMR Berghofer Medical Research Institute · AUUniversity of Maryland, Baltimore · USUniversity of Queensland · AUUniversity of Sydney · AU

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
New Function for the Serpin PAI-2 as a Regulator of pRbR01CA098369 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M. · 2003 to 2007
$1.5M
NEW FUNCTION SERPIN PAI 2 AS A REGULAR OF RBR56CA098369 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M · 2009 to 2009
$316k
NCI NIH HHS CA098369NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA098369NCI NIH HHS R56 CA098369
6 · The paper itself

Abstract

The serine protease inhibitor SerpinB2 (PAI-2), a major product of differentiating squamous epithelial cells, has recently been shown to bind and protect the retinoblastoma protein (Rb) from degradation. In human papillomavirus type 18 (HPV-18)-transformed epithelial cells the expression of the E6 and E7 oncoproteins is controlled by the HPV-18 upstream regulatory region (URR). Here we illustrate that PAI-2 expression in the HPV-18-transformed cervical carcinoma line HeLa resulted in the restoration of Rb expression, which led to the functional silencing of transcription from the HPV-18 URR. This caused loss of E7 protein expression and restoration of multiple E6- and E7-targeted host proteins, including p53, c-Myc, and c-Jun. Rb expression emerged as sufficient for the transcriptional repression of the URR, with repression mediated via the C/EBPbeta-YY1 binding site (URR 7709 to 7719). In contrast to HeLa cells, where the C/EBPbeta-YY1 dimer binds this site, in PAI-2- and/or Rb-expressing cells the site was occupied by the dominant-negative C/EBPbeta isoform liver-enriched transcriptional inhibitory protein (LIP). PAI-2 expression thus has a potent suppressive effect on HPV-18 oncogene transcription mediated by Rb and LIP, a finding with potential implications for prognosis and treatment of HPV-transformed lesions.

Indexed as

Gene SilencingBinding SitesCCAAT-Enhancer-Binding Protein-betaCell Transformation, ViralDNA-Binding ProteinsHeLa CellsHumansOncogene Proteins, ViralPapillomaviridaePlasminogen Activator Inhibitor 2Promoter Regions, GeneticProtein BindingProto-Oncogene Proteins c-junProto-Oncogene Proteins c-mycRetinoblastoma ProteinTranscription, GeneticCCAAT-Enhancer-Binding Protein-betaDNA-Binding ProteinsE6 protein, Human papillomavirus type 18E7 protein, Human papillomavirus type 18MYC protein, humanOncogene Proteins, ViralPlasminogen Activator Inhibitor 2Proto-Oncogene Proteins c-junProto-Oncogene Proteins c-mycRetinoblastoma ProteinTumor Suppressor Protein p53

Identifiers

PMID15767426
PMCPMC1061571
OpenAlexW2123766156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.